Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B Trial of the Combination of SJ733 and Tafenoquine for Radical Cure of P. Vivax Malaria in Comparison to Chloroquine-Tafenoquine

NCT07430592 is registered in ClinicalTrials.gov with R. Kiplin Guy as lead sponsor.

NCT NCT07430592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07430592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B Trial of the Combination of SJ733 and Tafenoquine for Radical Cure of P. Vivax Malaria in Comparison to Chloroquine-Tafenoquine
Lead sponsor
R. Kiplin Guy
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
November 20, 2028
Enrollment
104 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, malaria vivax, radical cure